In the present study using a chemokine/cytokine screen, we identified the chemokine CCL5 (formerly known as RANTES) as a candidate specific downstream target for aSMase. Regulation of CCL5 by aSMase was subsequently validated using both loss-of-function and gain-of-function models indicating that aSMase is both necessary and sufficient for CCL5 production. Interestingly, cells deficient in acid ceramidase (aCDase) also exhibited defects in CCL5 induction whereas cells deficient in sphingosine kinase-1 and -2 exhibited higher levels of CCL5, suggesting that sphingosine and not sphingosine-1-phosphate (S1P) is responsible for the positive signal to CCL5. Consistent with this, co-expression of aSMase and aCDase was sufficient to strongly induce CCL5. Taken together, these data identify a novel role for aSMase in chemokine elaboration by pro-inflammatory cytokines and highlight a novel and shared function for aSMase and aCDase.
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Once considered inert, structural components of biological membranes, sphingolipids (SPLs) are now recognized as biologically active molecules that have been implicated in the regulation of numerous cellular processes (1) . Ceramide (Cer, N-acyl-sphingosine) occupies a central position in SPL metabolism, serving as a metabolic precursor to more complex SPLs, such as sphingomyelin (SM) and the glycosphingolipids (1, 2) . Cer can also be deacylated by ceramidases (CDase) to form sphingosine (Sph) (3) , which in turn can be phosphorylated by sphingosine kinases (SphK) to generate sphingosine-1-phosphate (S1P) (4) . While Cer has been shown to play an important role in cellular stress signaling and cell death (5, 6) , S1P acts primarily as a pro-survival signal promoting growth, migration, and angiogenesis (7) . As such, enzymes of SPL metabolism determine the relative levels of Cer, Sph, and S1P; however, the precise roles and regulation of these enzymes are incompletely understood.
Acid sphingomyelinase (aSMase, SMPD1) is a soluble acid hydrolase that cleaves the phosphodiester bond of SM to form Cer. Mutations in the gene encoding aSMase give rise to Niemann-Pick disease (NPD) types A and B, a lysosomal storage disease with multi-organ involvement (8). In addition to its importance in preserving lysosomal function, aSMase has also been reported to be regulated by various cellular stressors to promote Cer formation (6) . Consequently, the aSMase/Cer pathway is considered a major component of the acute cellular stress response (9) . While primarily a lysosomal protein, aSMase can also be secreted extracellularly through alternative trafficking of a shared protein precursor, giving rise to secretory aSMase (S-SMase) (10,11). Notably, S-SMase secretion is enhanced by inflammatory cytokines (10) and serum levels of S-SMase are increased in mouse models of inflammation (12) , as well as a number of human disease states characterized by a pro-inflammatory state (13) (14) (15) .
Both SPLs and SPL metabolic enzymes have been linked to multiple inflammatory pathways (16, 17) , including cytokine-induced eicosanoid signaling (18, 19) , upregulation of adhesion molecules (20) , and regulation of cytokine elaboration (21) . However, the role for aSMase in inflammatory processes is less well understood; indeed, aSMase has been reported to exhibit both pro-and anti-inflammatory properties. For example, peritoneal macrophages from aSMase -/-mice produce higher levels of TNF-α in response to LPS challenge (22) , whereas Tlymphocytes from aSMase -/-mice exhibit defective elaboration of IFN-γ (23), and microglia from aSMase -/-mice are unable to produce IL-1β following purinergic stimulation (24) . Moreover, cells and tissues from NPD patients and aSMase-/-mice exhibit basal elevations in inflammatory markers (25) (26) (27) . Taken together, this suggests that chronic perturbation of sphingolipid metabolism may underlie dysregulation of the inflammatory response. However, another contributing factor is that aSMase-null cells lack both S-SMase and LSMase. In particular, the lack of tools available to address the contribution of S-SMase and L-SMase has limited study on the specific roles of these enzymes.
Recently, we described a role for S-SMase in cellular Cer formation using a mutant form of aSMase (S508A) that retained L-SMase function in the absence of S-SMase secretion (28) . However, the biological significance of this novel S-SMase/Cer pathway was not explored. Here, we now identify the chemokine CCL5 (formerly known as RANTES) as a novel effector of the SSMase/Cer pathway using both gain-of-function and loss-of-function analyses. Further analysis demonstrated a requirement for acid ceramidase (aCDase), but not SphK in the upregulation of CCL5. Based on these findings, we demonstrate a novel role for the S-SMase/Cer pathway in the regulation of the chemokine CCL5 and highlight a novel and shared function of aSMase and aCDase in the inflammatory response.
EXPERIMENTAL PROCEDURES
Materials-MCF7 breast carcinoma cells were obtained from ATCC (Manassas, VA). RPMI culture medium, fetal bovine serum, and Blasticidin S HCl were obtained from Invitrogen (Carlsbad, CA). Anti-V5 mouse monoclonal antibody was from Invitrogen. HRP-labeled secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Enhanced chemiluminescence kit was from ThermoScientific (Rockford, IL). Interleukin-1β was purchased from R&D Systems (Minneapolis, MN). Tumor necrosis factor-α was obtained from Peprotech (Rocky Hill, NJ). Myriocin (Myr) was obtained from Alexis Biochemicals/Enzo Life Sciences (Plymouth Meeting, PA). Fumonisin B1 (FB1) was obtained from Acros Organics (Geel, Belgium). The sphingosine kinase inhibitor SKI-II was from Calbiochem. Porcine brain sphingomyelin, D-erythro-sphingosine, and Derythro-sphingosine-1-phosphate were from Avanti Polar Lipids (Alabaster, AL). Desipramine, brefeldin A, and all other chemicals were obtained from Sigma (St. Louis, MO).
Cell culture-MCF7 cells were grown in RPMI-1640, supplemented with L-glutamine and 10% (v/v) fetal bovine serum. Monoclonal transfectants were isolated as described previously (29) . Stable overexpression was verified by Western blotting and confocal microscopy. Cells were maintained in 10%FBS/RPMI plus 7 µg/mL Blasticidin S-HCl. Cells were maintained at less than 80% confluence under standard incubator conditions (humidified atmosphere, 95% air, 5% CO 2 , 37˚C). Cells plated for experiments were cultured in the absence of Blasticidin. Control dermal fibroblasts (from the unaffected mother of a child with Lesch-Nyhan -Ctl; GM02226), Niemann-Pick type A dermal fibroblasts (NPD-1; GM13205, and NPD-2; GM16195), and Farber disease dermal fibroblasts (FD-1; GM02315, and FD-2; GM20017) were obtained from the Coriell Cell Repository. Cells were maintained in highglucose DMEM supplemented with 10% (v/v) fetal bovine serum without antibiotics. Control (L-N), NPD-1, FD-1, and FD-2 fibroblasts were used from passage 10-16 and NPD-2 cells from passage 15-20. MCF7 cells were treated with IL-1β and TNF-α in serum-free conditions (unless otherwise indicated), while dermal fibroblasts and MEFs were cultured and treated in serum-replete media.
Generation and immortalization of mouse embryonic fibroblasts-MEFs were generated from SphK1 +/− , and SphK2 +/− littermate matings in a C57BL/6J/129Sv background. Primary MEFs were harvested from E13.5 embryos as described earlier (30, 31) . Primary wild-type, SphK1
−/− , and SphK2 −/− MEFs (passages 3-4) were immortalized by retroviral infection with pBabe-hygro DD p53 expressing dominant-negative p53 (32) and selected with 150 µg/ml hygromycin for 14 days. MEFs were maintained in high-glucose DMEM supplemented with 10% (v/v) fetal bovine serum without antibiotics. For genotyping, genomic DNA was extracted from MEFs using a DNAEasy kit (Qiagen). For each cell line, 2 µL of DNA was combined with 1 µL each of three primers for either SphK1 or SphK2 and 20 µL PCR Platinum SuperMIx (Invitrogen) for a total reaction volume of 25 µL for PCR. The following primers (10 µM) from Integrated DNA Technologies (Coralville, IA) were used for SphK1: 5′-TGTCACCCATGAACCTGCTGTCCCTG-3′, 5′-AGAAGGCACTGGCTCCTCCAGAGGA-3′, and 5′-TCGTGCTTTACGGTATCGCCGCTCCC-3′ and the following primers were used for SphK2: Immunoprecipitation, SDS-PAGE, and Immunoblotting-V5-S-SMase and V5-S-aCDase were immunoprecipitated directly from conditioned media, as previously described secretion (28) . Briefly, conditioned media was first cleared of floating cells by brief centrifugation at 800 x g for 5 min (4°C). The supernatant containing S-SMase was then incubated overnight at 4°C with 1 µg/mL primary antibody (V5) and 1:20 protein A/G-agarose using a circular rotator. Bound protein was isolated by centrifugation (1 min, 12,000 rpm), washed three times with lysis buffer, followed by addition of 2x Laemmli buffer after which samples were boiled for 5 min. Equal volumes were subjected to SDS-PAGE (10% TrisHCl) using the BioRad Criterion system. Proteins were electrophoretically transferred to nitrocellulose membranes, blocked with PBS/0.1% Tween 20 (PBS-T) containing 5% nonfat dried milk, and incubated overnight at 4°C with primary antibody (V5-1:5,000) in PBS-T containing 5% nonfat dried milk. After overnight incubation with primary antibody, the blots were washed with PBS-T and incubated with the appropriate HRPconjugated secondary antibody (1:5000) in 5% milk/PBS-T. After washing (3x, 10 min -PBS-T), enhanced chemiluminescence was used to visualize bands.
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-
RNA was homogenized and extracted from cultured cells or mouse tissue using QIAShredder and RNeasy kits (QIAGEN), respectively. cDNA was synthesized from 1.0 µg RNA using Oligo-dT primers (Invitrogen) using Superscript II Reverse Transcriptase (Invitrogen) according to manufacturer's instruction. The standard RT-PCR reaction included 12.5 µL SYBR Green (Bio-Rad), 0.5 µL of 10 µM forward primer, 0.5 µL of 10 µM reverse primer, and 5.0 µL of diluted (1:10) cDNA adjusted to a final volume of 25.0 µL. The RT-PCR was performed using an iCycler (Bio-Rad) as follows: 3 min at 95°C, followed by cycles (n=40) consisting of a 10-s melt at 95°C, a 45-s annealing at 54°C, and an extension step of 45-sec at 68°C. All reactions were performed in triplicate. Primers were designed using Beacon Primer Design Software and purchased from Integrated DNA Technologies (Coralville, IA). Primers used for real-time PCR are as follows: forward human CCL5 5′-GCTGTCATCCTCATTGCTACTG-3′, reverse human CCL5 5′-TGGTGTAGAAATACTCCTTGATGTG-3′; forward human acid ceramidase (ASAH1) 5′-TCTTCCATGATCGCAGAACGCC-3′; reverse human acid ceramidase
Threshold cycle (C t ) values for target genes were normalized to the reference gene using Q-Gene software (28) to determine mean normalized expression.
In vitro acid SMase activity assay-The aSMase activity assay was performed as previously described (28) . Briefly, porcine brain sphingomyelin (0.2 mM) mixed with 14 Csphingomyelin (radiolabeled in the choline moiety, specific radioactivity = 1.5 x 10 5 cpm/µL) were presented to enzyme (conditioned media or cellular extracts) in Triton X-100 micelles in a buffer containing 250 mM sodium acetate (pH 5.00) and either 2.0 mM EDTA (L-SMase) or 0.2 mM ZnCl 2 (S-SMase) to a final concentration of 0.1 mM SM with either 0.1 mM ZnCl 2 (S-SMase) or 1.0 mM EDTA (L-SMase). The enzyme reaction was run for 30 min. at 37°C and terminated with the addition of 1.5 mL CHCl 3 : MeOH (2:1, v/v) followed by 0.4 mL water. Samples were vortexed, centrifuged (5 min, 3,000 rpm) and 0.8 mL of the aqueous/methanolic phase was removed for scintillation counting.
Sphingolipidomic Analysis-Adherent cells were washed twice with cold PBS and lysed in buffer containing 1% Triton X-100, 50 mM Tris (pH 7.4), 0.15 M NaCl, 1.0 mM EDTA, supplemented with protease and phosphatase inhibitors. Cellular homogenates (0.1-1.0 mg) were frozen at -80°C and then submitted for sphingolipidomic analysis by reverse-phase high pressure liquid chromatography coupled to electrospray ionization followed by separation by MS. Analysis of sphingoid bases, ceramides and sphingomyelins was performed on a Thermo Finnigan TSQ 7000 triple quadrupole mass spectrometer, operating in a multiple reactionmonitoring positive ionization mode, as described (34) .
Statistical Analysis-Data are represented as mean ± SEM, unless otherwise indicated. Unpaired student's t-test, 1-way ANOVA with Dunnett's post-test, and 2-way ANOVA with Bonferroni post-test statistical analyses were performed using Prism/GraphPad software with additional post-test analysis using the Prism/Graphpad website (http://www.graphpad.com/quickcalcs/posttest1.cf m).
RESULTS

CCL5 (RANTES) is upregulated by wild-type
aSMase; lack of effect of S508A aSMasePreviously, we demonstrated upregulation of SSMase in response to inflammatory cytokines (28) . To assess the functional role of S-SMase in the inflammatory response, we utilized our previously characterized MCF7 breast carcinoma cells lines stably expressing vector control (V5-LacZ), wild-type human aSMase (V5-aSMase WT ), or the secretion-incompetent aSMase mutant (V5-aSMase S508A ). Following treatment with vehicle or IL-1β, conditioned media were collected, and the levels of multiple cytokines and chemokines were analyzed utilizing a proteome profiler array (see EXPERIMENTAL PROCEDURES). In resting cells, levels of inflammatory cytokines/chemokines in the media were minimal. As expected, IL-1β (2.5 ng/mL, 18h) increased the levels of several analytes including CCL5/RANTES, sICAM-1, IL-8/CXCL8, and PAI-1. Of these, only CCL5 was markedly elevated in the aSMase WT cells relative to LacZ cells following IL-1β treatment (Fig. 1A-B) . Moreover, CCL5 levels were significantly increased in untreated aSMase WT cells suggesting that aSMase overexpression was sufficient to promote CCL5 upregulation.
These results suggest a novel effect for aSMase in specifically regulating the elaboration of CCL5.
Interestingly, the S508A aSMaseexpressing cells failed to demonstrate the upregulation of CCL5 in unstimulated cells, and did not enhance the IL-1β response (Fig. 1) . Since the S508A mutant is not secreted but retains lysosomal targeting and activity, these results suggest that the effects on CCL5 are specific to SSMase.
To validate these results, an ELISA specific for CCL5 was performed. Importantly, this confirmed the upregulation of CCL5 by wildtype, but not S508A acid SMase in MCF7 cells ( Fig. 2A) . As increased secretion of CCL5 in MCF7 has been reported to proceed in the absence of increased transcription (35) , the effect of aSMase overexpression on CCL5 mRNA was analyzed by qRT-PCR. Interestingly, CCL5 mRNA was elevated in untreated aSMase WT cells compared to both LacZ and aSMase S508A cells. Moreover, levels were further enhanced above control cells upon treatment with IL-1β (Fig. 2B) . Surprisingly, CCL5 mRNA levels in S508A cells were diminished compared to control cells, suggesting that the S508A aSMase mutant has a dominant-negative function. Taken together, these results indicate that overexpression of WT but not S508A aSMase is sufficient to increase CCL5 mRNA and protein levels. This identifies a novel target not only of aSMase, but also specifically of S-SMase. To our knowledge, this is the first putative downstream effector of the S-SMase pathway.
CCL5 elaboration is a late event in response to
TNF-α and IL-1β -As upregulation of S-SMase is a protracted event following inflammatory cytokine challenge (28, 36) , effectors of S-SMase would be expected to exhibit a similar delay. Accordingly, to establish a temporal relationship between S-SMase secretion and CCL5 elaboration, a time course of CCL5 release in MCF7 V5-aSMase WT MCF7 was determined following inflammatory cytokine challenge (Fig. 3) . Both TNF-α and IL-1β induced a time-dependent increase in CCL5, which became statistically significant after 12 hr. However, the effect of TNF-α on CCL5 was much stronger than IL-1β, which became more apparent at 18 and 24 hr. Importantly, the time course and extent of CCL5 elaboration following TNF-α and IL-1β treatment closely tracked that of S-SMase secretion and Cer generation (28) . These results demonstrate that the kinetics and extent of CCL5 induction in response to TNF-α and IL-1β closely track the upregulation of S-SMase.
Acid sphingomyelinase is required for CCL5 upregulation -To complement the findings with aSMase overexpression, the requirement for endogenous aSMase in CCL5 regulation was evaluated. Initially, multiple inhibitors of SPL enzymes/pathways were employed to determine if perturbation of SPL metabolism in general could alter CCL5 elaboration (Fig. 4A) . As can be seen, inhibition of de novo (myriocin (37) ) and salvage pathways of ceramide formation (fumonosin B1 (38)) had no effect on TNF-α-induced CCL5 release. Importantly, the indirect inhibitor of aSMase desipramine effectively blocked CCL5 upregulation, an effect comparable to brefeldin A, which inhibits the Golgi secretory pathway (39) . Desipramine is an established in vivo inhibitor of L-SMase (40), but its impact on constitutive or regulated S-SMase secretion has not been studied. To further explore this, stable aSMase WT MCF7 cells were utilized. As in parental MCF7 cells, desipramine strongly inhibited the elaboration of CCL5 in a dose-dependent manner in response to TNF-α in V5-aSMase WT MCF7 (Fig. 4B) . Interestingly, desipramine also inhibited TNF-α-mediated upregulation of S-SMase (Fig. 4C, D) . This is the first report suggesting that desipramine, considered an inhibitor of L-SMase, can also influence the secretion and action of S-SMase. Nevertheless, these data support the role of the SSMase pathway in regulation of CCL5/RANTES.
To consolidate the inhibitor data, a siRNA approach was utilized. As expected, aSMase siRNA significantly decreased endogenous LSMase activity (Fig. 4E) . Importantly, aSMase siRNA also decreased TNF-stimulated CCL5 release by 60-70% (Fig. 4E, F) .
Finally, to prove conclusively that aSMase was required for CCL5 upregulation, dermal fibroblasts were obtained from patients with Niemann-Pick disease type-A (NPD-1, NPD-2). Consequently, these fibroblasts exhibit complete loss of endogenous aSMase activity (Fig. 4G) . As can be seen, both NPD-1 and NPD-2 fibroblasts exhibited severe defects in CCL5 induction compared to control, aSMase-replete dermal fibroblasts (Fig. 4H) . Taken together, these results confirm that functional endogenous aSMase is required for CCL5 induction by TNF-α and IL-1β.
Acid SMase-deficient Niemann-Pick dermal fibroblasts exhibit defective ceramide and sphingoid base formation-The immediate metabolic product of aSMase-driven hydrolysis of SM is Cer (41); however, Cer can be metabolized to a number of other lipids. Ceramidases (CDases) deacylate Cer to form Sph (3), itself a potent signaling molecule, and Sph is further phosphorylated by SphK to form S1P (3, 42) . Accordingly, to determine if impaired CCL5 upregulation in aSMase-deficient cells was associated with impaired formation of Cer or downstream Cer metabolites, NPD-1, and NPD-2 fibroblasts were treated with vehicle or TNF-α and submitted for sphingolipidomic analysis.
As expected, both NPD-1 and NPD-2 cells displayed a marked elevation in total SM mass (Fig. 5A) and a significant decrease in total Cer levels consistent with impaired aSMase activity (Fig. 5B) . Interestingly, levels of Sph (Fig. 5C) and S1P (Fig. 5D) were also dramatically reduced in both NPD cell lines. Of note, TNF-α did not produce statistically significant elevations in the mass any of the sphingolipid analytes at the time point evaluated.
This may indicate that localized elevations in specific bioactive lipids are more biologically significant than changes in mass measured in cell homogenates. Nonetheless, these results indicate that in addition to influencing SM and Cer levels, aSMase deficiency affects Cer metabolites (Sph and S1P). This raises the possibility that defective formation of any (or all) of these lipid mediators may underlie the defective CCL5 response in NPD cells.
Absence of sphingosine kinase promotes CCL5 upregulation-Previous studies have implicated the SphK/S1P pathway in the regulation of inflammatory cytokine and chemokine elaboration (43) (44) (45) (46) including CCL5 (47) (48) (49) (50) . Thus, it became important to determine if Sph or S1P could be responsible for aSMase-mediated CCL5 induction. Consequently, the effect of RNAi-mediated knockdown of SphK1 and SphK2 on TNF-α-mediated CCL5 release in MCF7 was determined ( Fig. 6A-C) . As can be seen, SphK1 and SphK2 silencing resulted in a 1.5-2 fold elevation of CCL5 compared to control siRNA although this was to a greater extent with SphK2 siRNA. To confirm these results, MEFs from WT, SphK1-/-and SphK2-/-mice were obtained (Fig. 6D) and CCL5 elaboration was evaluated following treatment with TNF-α. While SphK1-/-MEFs exhibited a ~3-fold elevation over WT MEFs, CCL5 levels in SphK2-/-MEFs were 50-60 fold higher relative to WT MEFs (Fig. 6E) . Furthermore, qRT-PCR analysis demonstrated commensurate elevations in Ccl5 mRNA in SphK1 -/-and SphK2 -/-MEFs (Fig. 6F) . This exaggerated induction of CCL5 in SphK1-and SphK2-null cells suggests that Cer or Sph, but not S1P, is required for upregulation of CCL5 in response to TNF-α.
Acid ceramidase is required for CCL5 upregulation-
Acid ceramidase (aCDase) functions to degrade Cer within endo-lysosomes to generate Sph (51, 52) . However, aCDase is also secreted, can interact with S-SMase (53), and thus may contribute to metabolism of S-SMase-derived Cer. Accordingly, to determine if aSMase-derived Cer or Sph was responsible for CCL5 upregulation, the effect of aCDase siRNA on CCL5 production was evaluated. As can be seen, aCDase siRNA effectively decreased aCDase mRNA levels (Fig. 7A) . More importantly, aCDase siRNA significantly inhibited TNF-α induction of CCL5 suggesting that aCDase plays a role in CCL5 regulation (Fig. 7B) . To confirm this, dermal fibroblasts from patients with Farber disease (FD) which exhibit complete loss of aCDase activity (54) were obtained. As with the siRNA data, elaboration of CCL5 was significantly impaired in two different Farber disease cell lines (FD-1 and FD-2) compared to control cells. Moreover, this was true in response to both IL-1β and TNF-α (Fig. 7C) . Finally, to determine if aCDase was required for transcriptional upregulation of CCL5, CCL5 mRNA was evaluated in both NPD-1 and FD-1 cells in response to TNF-α (Fig. 7D) . Importantly, both NPD-1 and FD-1 cells failed to induce CCL5 mRNA in response to TNF-α, suggesting that both aSMase and aCDase are required for transcriptional induction of CCL5 presumably by promoting formation of Sph.
Co-expression of aSMase and aCDase is sufficient to induce CCL5-
To determine if the concerted action of aSMase and aCDase was sufficient to promote CCL5 upregulation, V5-aCDase was transiently transfected into vector control (LacZ) and aSMase WT MCF7 stable cell lines. Notably, aCDase transfection into control cells resulted in enhanced elaboration of CCL5 in response to TNF-α (Fig. 8) further supporting a role for this enzyme in CCL5 regulation. More strikingly, transfection of aCDase into aSMase WT cells resulted in a dramatic 13-fold upregulation of CCL5 over mock-transfected TNF-α-treated control cells (LacZ-mock + TNF-α: 525.5 ± 67.5 pg/mL/mg protein; aSMase + aCDase + TNF-α: 6988.1 ±951.4 pg/mL/mg protein). Moreover, coexpression of aSMase and aCDase was sufficient to increase levels of CCL5 nearly 40-fold (mocktransfected aSMase-ctl: 93.7 ±10.4 pg/mL/mg protein; aSMase + aCDase-ctl 3804.1 ±728.7 pg/mL/mg protein) even in the absence of an inflammatory stimulus. Taken together, these results indicate that both aSMase and aCDase contribute to CCL5 production and that coexpression of aSMase and aCDase is sufficient to promote CCL5 upregulation. In this study we set out to identify a downstream effector of the S-SMase/Cer pathway using our S508A aSMase mutant as a novel tool to distinguish the roles of S-SMase and L-SMase. Using these cells, we identified the β-chemokine CCL5 (previously known as RANTES) as a novel effector of the S-SMase/Cer pathway. However, upon further investigation we identified the Cer metabolite Sph as the candidate lipid for the regulation of CCL5, and not Cer itself. Generation of Sph from S-SMase-derived Cer required the action of aCDase. Importantly, the conversion of Sph to S1P was not required for CCL5 upregulation, as CCL5 levels were significantly elevated in cells lacking SphK, in particular SphK2. Taken together, these results demonstrate a novel role for both aSMase and aCDase in chemokine elaboration, and identify the first effector of the S-SMase/Cer pathway.
CCL5: a novel target of aSMase/S-SMase signaling-While aSMase has been implicated in various physiological and pathophysiological processes (41, 55) , the precise contribution of SSMase and L-SMase has remained unclear owing to the lack of molecular tools to dissect out their individual roles (56). Previously, we have characterized an S508A aSMase mutant as secretion incompetent while still maintaining LSMase activity (28) . Utilizing the S508A aSMase mutant as a novel tool to evaluate the role of SSMase, the chemokine CCL5 was identified as a candidate effector of the S-SMase/Cer pathway. Subsequently, pharmacological inhibitors of aSMase (i.e. desipramine), RNAi, and cells lacking aSMase activity (i.e. NPD fibroblasts) were used to demonstrate that endogenous aSMase is required for induction of CCL5 in response to pro-inflammatory cytokines.
Notably, upregulation of S-SMase and CCL5 are both protracted events in the inflammatory cascade (36, 57) . Importantly, the time course of CCL5 upregulation tracked that of S-SMase upregulation (28) , indicating a close temporal association between activation of the SSMase/Cer pathway and CCL5 induction. Taken together, these results demonstrate a novel role for aSMase in chemokine elaboration and identify CCL5 as a unique target of the S-SMase/Cer pathway. To our knowledge, this is the first proposed target of the S-SMase/Cer pathway.
Regulation of CCL5 by sphingolipids -
Several studies have investigated the role of SPLs in the regulation of inflammatory cytokines and chemokines (7), including CCL5 (47) (48) (49) , and the SphK/S1P pathway has been most closely associated with inflammatory responses (16) . However, the role of other SPL pathways in the elaboration of selective cytokines is becoming more apparent (21, 58) . The results of the present study demonstrate that both aSMase and aCDase are required for induction of CCL5 in the proinflammatory response. Furthermore, the overexpression of aSMase and aCDase is sufficient to drive CCL5 upregulation, presumably through the generation of Sph. Impaired conversion of Sph to S1P, primarily in cells lacking SphK2-/-resulted in overproduction of CCL5, providing additional support that Sph provides the primary signal to induce CCL5.
Efforts to demonstrate a relationship between cellular Sph levels and CCL5 induction were met with limited success (Supp. Fig. 1-4) . This is most likely due to the presence of the majority of cellular Sph in the lysosomes (greater than 90%) (18) , which then acts as a 'reservoir' for Sph, but also serves to mask the detection of significant changes in other compartments. Further complicating this analysis, exogenous Sph (and S1P) were unable to recapitulate the induction of CCL5 seen with other manipulations (Supp. Fig.  5-6 ). While SPL signaling processes at the plasma membrane may be more sensitive to exogenous SPLs (59) , at this time tools to evaluate specific lipid alterations in other regions of the cell are lacking, thus limiting further analysis. Because of the limited utility of these simple pharmacologic methods, we relied heavily on molecular approaches to begin to define the specific lipid(s) downstream of S-SMase action that drove CCL5 upregulation.
Based on this molecular triangulation, Sph represents the most likely lipid mediator, although given our limited capacity to interrogate compartment-specific SPL metabolism we cannot confirm a role for Sph at this time.
The dramatic hyper-induction of CCL5 in SphK2 -/-MEFs (>50-fold) suggests that aSMasederived Sph, and not S1P, drives CCL5 upregulation, but also provides a novel distinction between the functional roles of SphK1 and SphK2. While the precise mechanism whereby SPLs modulate CCL5 mRNA levels was not investigated, SphK2 was recently shown to modulate histone acetlylation thereby influencing gene transcription (60) . Interestingly, chromatin remodeling is an essential step in CCL5 induction in T lymphocytes (61) , and inhibition of HDACs has been shown to prevent upregulation of CCL5 (62) . Future studies will be required to determine the precise mechanism whereby specific SPLs modulate CCL5 mRNA levels.
Importantly, regulation of CCL5 varies among different cell types (63) . Although first described in T-lymphocytes (64), it is now well established that multiple cells produce CCL5 including platelets (65), vascular smooth muscle cells (66) , epithelial cells (67) , and fibroblasts (68) . While some cell types store CCL5 in granules ready for release (e.g. CD8+ T lymphocytes (69), platelets (65)), CCL5 induction in most cells requires transcriptional upregulation of CCL5 mRNA (70) . Several constitutive and regulated transcription factors participate in CCL5 transcriptional activation (71), including NF-κB (72) and STAT-3 (66) . For example, upregulation of CCL5 in primary T-lymphocytes occurs over 3 to 5 days requiring a unique complement of transcription factors that are subject to multiple levels of regulation (61, 63, 73, 74) . CCL5 is then stored in granules and can be released upon T-cell receptor activation. Notably, release of CCL5 from activated T-lymphocyte granules does not appear to require aSMase (23), suggesting that upregulation of CCL5 mRNA, rather than secretion itself, is regulated by SPLs. Future studies will be required to elucidate the mechanisms by which SPLs regulate CCL5 mRNA levels.
Compartmentalization of sphingolipid signaling -Several lines of evidence indicate an essential role for SPLs, in particular Sph, in the upregulation of CCL5 following TNF-α or IL-1β treatment. However, these results also suggest that regulation of CCL5 requires compartmentspecific generation of bioactive lipids. First, impaired upregulation of CCL5 in MCF7 expressing the secretion-incompetent S508A mutant suggests the involvement of S-SMase (and not L-SMase). Secondly, modulation of SPL metabolism in general was insufficient to influence CCL5 elaboration, as inhibition of de novo SPL biosynthesis or the ceramide salvage pathway with myrocin and fumonisin B1, respectively, did not alter TNF-α-induced CCL5 elaboration. Third, upregulation of CCL5 was sensitive to desipramine, a cationic amphiphilic drug that accumulates in acidic organelles and inhibits both aSMase and aCDase function (40, 75) , and prevented S-SMase secretion in response to TNF-α. Fourth, overproduction of CCL5 was evident in SphK2 -/-MEFs, to a far greater degree than SphK1 -/-MEFs. SphK2 localizes to the nucleus and ER, while SphK1 is primarily cytosolic (76) (77) (78) , suggesting that the site of Sph (and S1P) formation determines its biological function. Fifth, addition of exogenous Sph was insufficient to induce of CCL5, and exogenous S1P was unable to restore elevated CCL5 to normal levels in SphK2 -/-MEFs (Supp. Fig. 5-6 ). Taken together, these results suggest the involvement of a specific subcellular compartment, with a defined complement of SPL enzymes (i.e. aSMase, aCDase, SphK2) functioning to regulate the levels of CCL5. Identifying the specific cellular/subcellular site of Sph generation will be crucial for future mechanistic studies, and is an ongoing project in our laboratory.
Biological role of the aSMase/aCDase/CCL5 axis-While the results of this study indicate that both aSMase and aCDase are necessary and sufficient to induce CCL5, the precise role of aSMase and aCDase in CCL5-mediated biological processes is not known. CCL5 (RANTES) is a C-C type (β-) chemokine that promotes the chemotaxis of a variety of cells, including monocytes, T-lymphocytes, dendritic cells, basophils, eosinophils, and mast cells to sites of inflammation (79, 80) . CCL5 is important for physiologic inflammatory responses, as failure to upregulate CCL5 leads to impaired viral clearance (81) and defective type IV hypersensitivity responses owing to impaired T-cell function (82) . In patients lacking aSMase and aCDase (i.e. patients with NPD or FD, respectively), dysregulation of inflammatory responses is often observed, but alterations in CCL5 levels or CCL5-mediated responses have not been determined. However, altered levels of various chemokines have been detected both in both patients with NPD and in aSMase -/-mice, including MIP-1α, CCL2, and CCL18 (25) (26) (27) . In FD (also known as Farber lipogranulomatosis), chronic inflammation resulting from leukocyte dysregulation leads to the formation of pathologic granulomas (83) . Finally, excessive elaboration of CCL5 has also been implicated in several disease states, including allograft transplant rejection (84), asthma (85) , rheumatoid arthritis (86) , atherosclerosis (87, 88) , endometriosis (89) , and several cancers (90) (91) (92) (93) . Thus, while the roles of aSMase and aCDase in CCL5-mediated biological processes have yet to be defined, given the multiple roles attributed to the action of CCL5, interventions aimed at inhibiting aSMase and/or aCDase may prove useful in the modulation of CCL5 and CCL5-mediated disease processes.
Conclusion-In this study we identify aSMase (S-SMase) and aCDase as novel regulators of the chemokine CCL5, previously known as RANTES. Furthermore, SphK2 appears to be a negative regulator of CCL5, as loss of SphK2 results in overproduction of CCL5. As CCL5 has been associated with several diseases, including atherosclerosis, asthma, and cancer, modulation of SPLs may represent a novel approach to modify CCL5 elaboration to better manage and treat a variety of different human diseases. (V5-aSMase WT ), or the secretion-incompetent aSMase mutant (V5-aSMase S508A ) were treated with vehicle (PBS) or IL-1β (2.5 ng/mL) for 18 hr. A) Cell-free conditioned media were collected and subjected to cytokine/chemokine analysis using a Cytokine Panel Array (see EXPERIMENTAL PROCEDURES) to identify any inflammatory mediators that were specifically up-or down-regulated in WT, but not S508A MCF7. B) Densitometric analysis of analyte data was performed using NIH Image J as described in EXPERIMENTAL PROCEDURES. Integrated pixel densities of the various analyates were normalized to internal positive controls (+ ctl) (n=1). WT , and V5-aSMase S508A were treated with vehicle (PBS) or IL-1β (2.5 ng/mL) for 18 hr. A) Cell-free conditioned media were collected, and CCL5 protein levels were determined using by ELISA. B) CCL5 mRNA levels were determined by RT-PCR in response to 18 hr PBS (Ctl) or IL-1β (2.5 ng/mL) and were normalized to β-actin (see EXPERIMENTAL PROCEDURES) (n≥3; 2-way ANOVA with Bonferroni post-test, *p<.05, **p<.01, ***p<.001 vs. LacZ, #p<.05 vs. untreated). WT were treated with vehicle (PBS), IL-1β (2.5 ng/mL), or TNF-α (50 ng/mL) for the indicated time points. Cell-free conditioned media were collected, and CCL5 protein levels were determined using by ELISA (n≥3; 2-way ANOVA with Bonferroni posttest, *p<.05, **p<.01, ***p<.001 vs. LacZ, #p<.05 vs. untreated). B) CCL5 mRNA levels were determined by RT-PCR in response to PBS (Ctl), IL-1β (2.5 ng/mL) and TNF-α (50 ng/mL) for the indicated times and normalized to β-actin (see EXPERIMENTAL PROCEDURES) (n≥3; 2-way ANOVA with Bonferroni post-test, ***p<.001 vs. Ctl). In cells with aSMase, aCDase, and SphK1/2, upregulation of CCL5 in response to TNF-α or IL-1β proceeds normally. In cells, lacking either aSMase or aCDase, upregulation of CCL5 is impaired and Sph levels are diminished. On the other hand, cells lacking SphK1/2 exhibited significantly higher levels of CCL5 following inflammatory challenge and exhibit elevated Sph levels. In the absence of an inflammatory stimulus, overexpression of either aSMase or aCDase can modestly increase CCL5 production, but co-expression of aSMase and aCDase is sufficient for a dramatic upregulation of CCL5 albeit without significant changes in Sph mass. 
